Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVL plus carvedilol versus EVL plus propranolol for secondary prevention after esophageal variceal bleeding in cirrhosis
ChiCTR2400089692Phase 4Not yet recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in Cirrhosis, esophageal varices and Portal Hypertension (PH) comparing Carvedilol group with Propranolol group (2 arms). Primary endpoint: Variceal rebleeding or all-cause death. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
carvedilolpropranolol
03
Conditions
Cirrhosisesophageal varicesPortal Hypertension (PH)
Beyond the preview
Go deeper on ChiCTR2400089692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089692.